# US 2008/0187978 A1 · Anti-inflammatory medicaments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187978 A1
- Document ID: US20080187978A1
- Status: Published application
- Kind: A1
- Application number: 11/337,245
- Filed: 2006-01-20
- Published: 2008-08-07
- Earliest claimed: 2002-12-31
- Inventors: Daniel L. Flynn; Peter A. Petillo
- Web page: https://patentgrep.com/patent/US20080187978A1

## CPC

- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/16: Central respiratory analeptics
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 295/10: substituted by doubly bound oxygen or sulphur atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.

## Claims

### Claim 1

An adduct comprising a molecule binding with a kinase, said molecule having the formula
wherein:
R1 is selected from the group consisting of aryls and heteroaryls;
each X and Y is individually selected from the group consisting of —O—, —S—, —NR6—, —NR6SO2—, —NR6CO—, alkynyls, alkenyls, alkylenes, —O(CH2)h—, and —NR6(CH2)h—, where each h is individually selected from the group consisting of 1, 2, 3, or 4, and where for each of alkylenes, —O(CH2)h—, and —NR6(CH2)h—, one of the methylene groups present therein may be optionally double-bonded to a side-chain oxo group except that where —O(CH2)h— the introduction of the side-chain oxo group does not form an ester moiety;
A is selected from the group consisting of aromatic, monocycloheterocyclic, and bicycloheterocyclic rings;
D is phenyl or a five- or six-membered heterocyclic ring selected from the group consisting of pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, thienyl, pyridyl, and pyrimidyl;
E is selected from the group consisting of phenyl, pyridinyl, and pyrimidinyl;
L is selected from the group consisting of —C(O)— and —S(O)2—;
j is 0 or 1;
m is 0 or 1;
n is 0 or 1;
p is 0 or 1;
q is 0 or 1;
t is 0 or 1;
Q is selected from the group consisting of
each R4 group is individually selected from the group consisting of —H, alkyls, aminoalkyls, alkoxyalkyls, aryls, aralkyls, heterocyclyls, and heterocyclylalkyls except when the R4 substituent places a heteroatom on an alpha-carbon directly attached to a ring nitrogen on Q;
when two R4 groups are bonded with the same atom, the two R4 groups optionally form an alicyclic or heterocyclic 4-7 membered ring;
each R5 is individually selected from the group consisting of —H, alkyls, aryls, heterocyclyls, alkylaminos, arylaminos, cycloalkylaminos, heterocyclylaminos, hydroxys, alkoxys, aryloxys, alkylthios, arylthios, cyanos, halogens, perfluoroalkyls, alkylcarbonyls, and nitros;
each R6 is individually selected from the group consisting of —H, alkyls, allyls, and β-trimethylsilylethyl;
each R8 is individually selected from the group consisting of alkyls, aralkyls, heterocyclyls, and heterocyclylalkyls;
each R9 group is individually selected from the group consisting of —H, —F, and alkyls, wherein when two R9 groups are geminal alkyl groups, said geminal alkyl groups may be cyclized to form a 3-6 membered ring;
G is alkylene, N(R6), O;
each Z is individually selected from the group consisting of —O— and —N(R4)—; and
each ring of formula (III) optionally includes one or more of R7, where R7 is a noninterfering substituent individually selected from the group consisting of —H, alkyls, aryls, heterocyclyls, alkylaminos, arylaminos, cycloalkylaminos, heterocyclylaminos, hydroxys, alkoxys, aryloxys, alkylthios, arthylthios, cyanos, halogens, nitrilos, nitros, alkylsulfinyls, alkylsulfonyls, aminosulfonyls, and perfluoroalkyls.

### Claim 2 (depends on 1)

The adduct of claim 1, said molecule binding at the region of a switch control pocket of said kinase.

### Claim 3 (depends on 2)

The adduct of claim 2, said switch control pocket of said kinase comprising an amino acid residue sequence operable for binding to said Formula (III) molecule.

### Claim 4 (depends on 2)

The adduct of claim 2, said switch control pocket selected from the group consisting of simple, composite and combined switch control pockets.

### Claim 5 (depends on 4)

The adduct of claim 4, said region being selected from the group consisting of the α-C helix, the α-D helix, the catalytic loop, the switch control ligand sequence, the C-terminal residues, the glycine rich loop residues, and combinations thereof.

### Claim 6 (depends on 5)

The adduct of claim 5, said α-C helix including SEQ ID NO. 2.

### Claim 7 (depends on 5)

The adduct of claim 5, said catalytic loop including SEQ ID NO. 3.

### Claim 8 (depends on 5)

The adduct of claim 5, said switch control ligand sequence being selected from the group consisting of SEQ ID NO. 4, SEQ ID NO. 5, and combinations thereof.

### Claim 9 (depends on 5)

The adduct of claim 5, said C-lobe residues selected from SEQ ID NO. 6.

### Claim 10 (depends on 5)

The adduct of claim 5, said glycine rich loop residues taken from SEQ ID NO. 7.

### Claim 11 (depends on 1)

The adduct of claim 1, said kinase selected from the group consisting of the consensus wild type sequence and disease polymorphs thereof.

### Claim 12 (depends on 1)

The adduct of claim 1, said molecule having the formula
wherein:
R1 is selected from the group consisting of aryls and heteroaryls;
each X and Y is individually selected from the group consisting of —O—, —S—, —NR6—, —NR6SO2—, —NR6CO—, alkynyls, alkenyls, alkylenes, —O(CH2)h—, and —NR6(CH2)h—, where each h is individually selected from the group consisting of 1, 2, 3, or 4, and where for each of alkylenes, —O(CH2)h—, and —NR6(CH2)h—, one of the methylene groups present therein may be optionally double-bonded to a side-chain oxo group except that where —O(CH2)h— the introduction of the side-chain oxo group does not form an ester moiety;
A is selected from the group consisting of aromatic, monocycloheterocyclic, and bicycloheterocyclic rings;
D is phenyl or a five- or six-membered heterocyclic ring selected from the group consisting of pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, thienyl, pyridyl, and pyrimidyl;
E is selected from the group consisting of phenyl, pyridinyl, and pyrimidinyl;
L is selected from the group consisting of —C(O)— and —S(O)2—;
j is 0 or 1;
m is 0 or 1;
n is 0 or 1;
p is 0 or 1;
q is 0 or 1;
t is 0 or 1;
Q is selected from the group consisting of
each R4 group is individually selected from the group consisting of —H, alkyls, aminoalkyls, alkoxyalkyls, aryls, aralkyls, heterocyclyls, and heterocyclylalkyls except when the R4 substituent places a heteroatom on an alpha-carbon directly attached to a ring nitrogen on Q;
when two R4 groups are bonded with the same atom, the two R4 groups optionally form an alicyclic or heterocyclic 4-7 membered ring;
each R5 is individually selected from the group consisting of —H, alkyls, aryls, heterocyclyls, alkylaminos, arylaminos, cycloalkylaminos, heterocyclylaminos, hydroxys, alkoxys, aryloxys, alkylthios, arylthios, cyanos, halogens, perfluoroalkyls, alkylcarbonyls, and nitros;
each R6 is individually selected from the group consisting of —H, alkyls, allyls, and β-trimethylsilylethyl;
each R8 is individually selected from the group consisting of alkyls, aralkyls, heterocyclyls, and heterocyclylalkyls;
each R9 group is individually selected from the group consisting of —H, —F, and alkyls, wherein when two R9 groups are geminal alkyl groups, said geminal alkyl groups may be cyclized to form a 3-6 membered ring; and
G is alkylene, N(R6), O;
each Z is individually selected from the group consisting of —O— and —N(R4)—;
each ring of formula (IA) optionally includes one or more of R7, where R7 is a noninterfering substituent individually selected from the group consisting of —H, alkyls, aryls, heterocyclyls, alkylaminos, arylaminos, cycloalkylaminos, heterocyclylaminos, hydroxys, alkoxys, aryloxys, alkylthios, arthylthios, cyanos, halogens, nitrilos, nitros, alkylsulfinyls, alkylsulfonyls, aminosulfonyls, and perfluoroalkyls;
except that:
when Q is Q-3 or Q-4, then the compound of formula (IA) is not
when Q is Q-7, q is 0, and R5 and D are phenyl, then A is not phenyl, oxazolyl, pyridyl, pyrimidyl, pyrazolyl, or imidazolyl;
when Q is Q-7, R5 is —OH, Y is —O—, —S—, or —CO—, m is 0, n is 0, p is 0, and A is phenyl, pyridyl, or thiazolyl, then D is not thienyl, thiazolyl, or phenyl;
when Q is Q-7, R5 is —OH, m is 0, n is 0, p is 0, t is 0, and A is phenyl, pyridyl, or thiazolyl, then D is not thienyl, thiazolyl, or phenyl;
when Q is Q-7, then the compound of formula (IA) is not
when Q is Q-8, then Y is not —CH2O—;
when Q is Q-8, the compound of formula (IA) is not
when Q is Q-9, then the compound of formula (IA) is not
when Q is Q-10, t is 0, and E is phenyl, then any R7 on E is not an o-alkoxy;
when Q is Q-10, then the compound of formula (IA) is not
when Q is Q-11, t is 0, and E is phenyl, then any R7 on E is not an o-alkoxy;
when Q is Q-11, then the compound of formula (IA) is not
when Q is Q-15, then the compound of formula (IA) is not
when Q is Q-16 and Y is —NH—, then
of formula (IA) is not biphenyl;
when Q is Q-16 and Y is —S—, then
of formula (IA) is not phenylsulfonylaminophenyl or phenylcarbonylaminophenyl;
when Q is Q-16 and Y is —SO2NH—, then the compound of formula (IA) is not
when Q is Q-16 and Y is —CONH—, then
of formula (IA) is not imidazophenyl;
when Q is Q-16 and Y is —CONH—, then the compound of formula (IA) is not
when Q is Q-16 and t is 0, then
of formula (IA) is not phenylcarbonylphenyl, pyrimidophenyl, phenylpyrimidyl, pyrimidyl, or N-pyrolyl;
when Q is Q-17, then the compound of formula (IA) is not
when Q is Q-21, then the compound of formula (IA) is not
when Q is Q-22, then the compound of formula (IA) is selected from the group consisting of
when Q is Q-22 and q is 0, then the compound of formula (IA) is selected from the group consisting of
when Q is Q-23, then the compound of formula (IA) is not
when Q is Q-24, Q-25, Q-26, or Q-31, then the compound of formula (IA) is selected from the group consisting of
wherein each W is individually selected from the group consisting of —CH— and —N—;
each G1 is individually selected from the group consisting of —O—, —S—, and —N(R4)—; and
* denotes the point of attachment to Q-24, Q-25, Q-26, or Q-31 as follows:
wherein each Z is individually selected from the group consisting of —O— and —N(R4)—;
when Q is Q-31, then the compound of formula (IA) is not
when Q is Q-28 or Q-29 and t is 0, then the compound of formula (IA) is not
when Q is Q-28 or Q-29 and Y is an ether linkage, then the compound of formula (IA) is not
when Q is Q-28 or Q-29 and Y is —CONH—, then the compound of formula (IA) is not
when Q is Q-32, then
is not biphenyl, benzoxazolylphenyl, pyridylphenyl or bipyridyl;
when Q is Q-32, Y is —CONH—, q is 0, m is 0, and
of formula (IA) is —CONH—, then A is not phenyl;
when Q is Q-32, q is 0, m is 0, and
is —CONH—, then the compound of formula (IA) is not
when Q is Q-32, D is thiazolyl, q is 0, t is 0, p is 0, n is 0, and m is 0, then A is not phenyl or 2-pyridone;
when Q is Q-32, D is oxazolyl or isoxazolyl, q is 0, t is 0, p is 0, n is 0, and m is 0, then A is not phenyl;
when Q is Q-32, D is pyrimidyl q is 0, t is 0, p is 0, n is 0, and m is 0, then A is not phenyl;
when Q is Q-32 and Y is an ether linkage, then
of formula (IA) is not biphenyl or phenyloxazolyl;
when Q is Q-32 and Y is —CH═CH—, then
of formula (IA) is not phenylaminophenyl;
when Q is Q-32, then the compound of formula (IA) is not
when Q is Q-35 as shown
wherein G is selected from the group consisting of —O—, —S—, —NR4—, and —CH2—, k is 0 or 1, and u is 1, 2, 3, or 4, then
is selected from the group consisting of
except that the compound of formula (IA) is not

### Claim 13

An adduct comprising a molecule binding with a p 38-alpha kinase, said molecule having the formula
A-T-(L)n-(NH)p-D-(E)q-(Y)t-Q (IB)
wherein:
Y is selected from the group consisting of —O—, —S—, —NR6—, —NR6SO2—, —NR6CO—, alkynyls, alkenyls, alkylenes, —O(CH2)h—, and —NR6(CH2)h—, where each h is individually selected from the group consisting of 1, 2, 3, or 4, and where for each of alkylenes, —O(CH2)h—, and —NR6(CH2)h—, one of the methylene groups present therein may be optionally double-bonded to a side-chain oxo group except that where —O(CH2)h— the introduction of the side-chain oxo group does not form an ester moiety;
A is selected from the group consisting of aromatic, monocycloheterocyclic, and bicycloheterocyclic rings; and most preferably phenyl, naphthyl, pyridyl, pyrimidyl, thienyl, furyl, pyrrolyl, thiazolyl, isothiazolyl, oxaxolyl, isoxazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, indolyl, indazolyl, benzimidazolyl, benzotriazolyl, isoquinolyl, quinolyl, benzothiazolyl, benzofuranyl, benzothienyl, pyrazolylpyrimidinyl, imidazopyrimidinyl, purinyl, and
where each W1 is individually selected form the group consisting of —CH— and —N—.
D is phenyl or a five- or six-membered heterocyclic ring selected from the group consisting of pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, thienyl, pyridyl, and pyrimidyl;
E is selected from the group consisting of phenyl, pyridinyl, and pyrimidinyl;
L is selected from the group consisting of —C(O)— and —S(O)2—;
T is N6, O, alkylene, —O(CH2)h—, or —NR6(CH2)h—, where each h is individually selected from the group consisting of 1, 2, 3, or 4, or T is absent wherein A is directly bonded to -(L)n(NH)p-D-(E)q-(Y)t-Q;
n is 0 or 1;
p is 0 or 1;
q is 0 or 1;
t is 0 or 1;
v is 1, 2, or 3;
x is 1 or 2;
Q is selected from the group consisting of formulae Q36-Q59, inclusive, said Q36-Q59 groups being selected from the group consisting of
each R4 group is individually selected from the group consisting of —H, alkyls, aminoalkyls, alkoxyalkyls, aryls, aralkyls, heterocyclyls, and heterocyclylalkyls except when the R4 substituent places a heteroatom on an alpha-carbon directly attached to a ring nitrogen on Q;
when two R4 groups are bonded with the same atom, the two R4 groups optionally form an alicyclic or heterocyclic 4-7 membered ring;
each R6 is individually selected from the group consisting of —H, alkyls, allyls, and B-trimethylsilylethyl;
each R8 is individually selected from the group consisting of alkyls, phenyl, naphthyl, aralkyls, heterocyclyls, and heterocyclylalkyls;
each R9 group is individually selected from the group consisting of —H, —F, and alkyls, wherein when two R9 groups are geminal alkyl groups, said geminal alkyl groups may be cyclized to form a 3-6 membered ring;
each R9, group is individually selected from the group consisting of —F, and alkyls, wherein when two R9, groups are geminal alkyl groups, said geminal alkyl groups may be cyclized to form a 3-6 membered ring;
each R10 is alkyl or perfluoroalkyl;
G is alkylene, N(R6), O; and
each Z is individually selected from the group consisting of —O— and —N(R4)—; and each ring of formula (IB) optionally includes one or more of R7′, where R7′ is a substituent individually selected from the group consisting of —H, alkyls, aryls, heterocyclyls, alkylaminos, arylaminos, cycloalkylaminos, heterocyclylaminos, hydroxys, alkoxys, perfluoroalkoxys, aryloxys, alkylthios, arthylthios, cyanos, halogens, nitrilos, nitros, alkylsulfinyls, alkylsulfonyls, aminosulfonyls, perfluoroalkyls; aminooxaloylamino; alkylaminooxaloylamino; dialkylaminooxaloylamino; morpholinooxaloylamino; piperazinooxaloylamino; alkoxycarbonylamino; heterocyclyloxycarbonylamino; heterocyclylalkyloxycarbonylamino; heterocyclylcarbonylamino; heterocyclylalkylcarbonylamino; aminoalkyloxycarbonylamino; alkylaminoalkyloxycarbonylamino; or dialkylaminoalkyloxycarbonylamino,

### Claim 14 (depends on 13)

The adduct of claim 13, said molecule binding at the region of a switch control pocket of said kinase.

### Claim 15 (depends on 14)

The adduct of claim 14, said switch control pocket of said kinase comprising an amino acid residue sequence operable for binding to said molecule.

### Claim 16 (depends on 14)

The adduct of claim 14, said switch control pocket selected from the group consisting of simple, composite and combined switch control pockets.

### Claim 17 (depends on 14)

The adduct of claim 14, said region being selected from the group consisting of the α-C helix, the α-D helix, the catalytic loop, the switch control ligand sequence, the C-terminal residues, the glycine rich loop residues, and combinations thereof.

### Claim 18 (depends on 17)

The adduct of claim 17, said α-C helix including SEQ ID NO. 2.

### Claim 19 (depends on 17)

The adduct of claim 17, said catalytic loop including SEQ ID NO. 3.

### Claim 20 (depends on 17)

The adduct of claim 17, said switch control sequence being selected from the group consisting of SEQ ID NO. 4, SEQ ID NO. 5, and combinations thereof.

### Claim 21 (depends on 17)

The adduct of claim 17, said C-lobe residues selected from the group consisting of SEQ ID NO. 6.

### Claim 22 (depends on 17)

The adduct of claim 17, said glycine rich loop residues including SEQ ID NO. 7.

### Claim 23 (depends on 13)

The adduct of claim 13, said kinase selected from the group consisting of the consensus wild type P 38-alpha kinase sequence and disease polymorphs thereof.

### Claim 24

A kinase-modulator adduct comprising a p38-alpha kinase having a switch control pocket with a non-naturally occurring molecule bound to the kinase at the region of said switch control pocket, said molecule serving to at least partially regulate the biological activity of said protein by inducing or restricting the conformation of the protein.

### Claim 25 (depends on 24)

The adduct of claim 24, said molecule serving to induce a conformation change in said kinase.

### Claim 26 (depends on 24)

The adduct of claim 24, said molecule serving to restrict a conformation change in said kinase.

### Claim 27 (depends on 24)

The adduct of claim 24, said region of the switch control pocket being selected from the group consisting of the α-C helix, the α-D helix, the catalytic loop, the switch control ligand sequence, the C-terminal residues, the glycine rich loop residues, and combinations thereof.

### Claim 28 (depends on 27)

The adduct of claim 27, said α-C helix including SEQ ID NO. 2.

### Claim 29 (depends on 27)

The adduct of claim 27, said catalytic loop including SEQ ID NO. 3.

### Claim 30 (depends on 27)

The adduct of claim 27, said switch control sequence being selected from the group consisting of SEQ ID NO. 4, SEQ ID NO. 5, and combinations thereof.

### Claim 31 (depends on 27)

The adduct of claim 27, said C-lobe residues selected from the group consisting of SEQ ID NO. 6.

### Claim 32 (depends on 27)

The adduct of claim 27, said glycine rich loop residues including SEQ ID NO. 7.

### Claim 33 (depends on 24)

The adduct of claim 24, said kinase also having a switch control ligand, said ligand interacting in vivo with said pocket to regulate the conformation and biological activity of said kinase such that the kinase will assume a first conformation and a first biological activity upon said ligand-pocket interaction, and will assume a second, different conformation and biological activity in the absence of said ligand-pocket interaction.

### Claim 34 (depends on 24)

The adduct of claim 24, said pocket being an on-pocket, said molecule binding with said kinase at the region of said on-pocket as an agonist.

### Claim 35 (depends on 24)

The adduct of claim 24, said pocket being an on-pocket, said molecule binding with said kinase at the region of said on-pocket as an antagonist.

### Claim 36 (depends on 24)

The adduct of claim 24, said pocket being an off-pocket, said molecule binding with said kinase at the region of said off-pocket as an agonist.
